ES2176354T3 - Uso de nebivolol como agente anti-aterogenico. - Google Patents

Uso de nebivolol como agente anti-aterogenico.

Info

Publication number
ES2176354T3
ES2176354T3 ES95942209T ES95942209T ES2176354T3 ES 2176354 T3 ES2176354 T3 ES 2176354T3 ES 95942209 T ES95942209 T ES 95942209T ES 95942209 T ES95942209 T ES 95942209T ES 2176354 T3 ES2176354 T3 ES 2176354T3
Authority
ES
Spain
Prior art keywords
aterogenic
nebivolol
agent
propensive
profilactic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95942209T
Other languages
English (en)
Inventor
Chaffoy De Courcelles Didie De
Anne Simone Josephine Lesage
Josepha Eduarda Maria F Leysen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2176354T3 publication Critical patent/ES2176354T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE UN DERIVADO DE {AL},{AL}'' IMINOBIS(METILEN)BIS[2 DICAMENTO PARA EL TRATAMIENTO TERAPEUTICO O PROFILACTICO DE PERSONAS QUE PADECEN O SON PROPENSAS A ENFERMEDADES DEGENERATIVAS Y TRASTORNOS DEL SISTEMA NERVIOSO Y VASCULAR ASOCIADAS AL ESTRES OXIDATIVO.
ES95942209T 1994-12-28 1995-12-21 Uso de nebivolol como agente anti-aterogenico. Expired - Lifetime ES2176354T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94203775 1994-12-28

Publications (1)

Publication Number Publication Date
ES2176354T3 true ES2176354T3 (es) 2002-12-01

Family

ID=8217503

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95942209T Expired - Lifetime ES2176354T3 (es) 1994-12-28 1995-12-21 Uso de nebivolol como agente anti-aterogenico.

Country Status (20)

Country Link
US (2) US5874461A (es)
EP (1) EP0801564B1 (es)
JP (1) JPH10511655A (es)
KR (1) KR100264348B1 (es)
CN (1) CN1167418C (es)
AT (1) ATE214924T1 (es)
AU (1) AU700364B2 (es)
CA (1) CA2207333C (es)
CZ (1) CZ287513B6 (es)
DE (1) DE69526120T2 (es)
DK (1) DK0801564T3 (es)
ES (1) ES2176354T3 (es)
FI (1) FI118884B (es)
HU (1) HU226208B1 (es)
NO (1) NO315687B1 (es)
NZ (1) NZ298074A (es)
PT (1) PT801564E (es)
SI (1) SI0801564T1 (es)
SK (1) SK282144B6 (es)
WO (1) WO1996019987A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT801564E (pt) * 1994-12-28 2002-09-30 Janssen Pharmaceutica Nv Utilizacao de nebivolol como agente anti-aterogernico
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
JP2000207219A (ja) * 1999-01-18 2000-07-28 Fujitsu Ten Ltd 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
WO2002087508A2 (en) 2001-05-02 2002-11-07 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
JP4599292B2 (ja) * 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
CA2580584C (en) 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
CN101006081B (zh) 2004-07-30 2011-02-09 托伦特药物有限公司 奈必洛尔及其药学可接受盐、制备方法以及奈必洛尔的药物组合物
AP2764A (en) * 2005-01-31 2013-09-30 Mylan Lab Inc Hydroxylated nebivolol metabolites
ES2714900T3 (es) 2005-06-01 2019-05-30 Bioelectron Tech Corp Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
WO2007100652A2 (en) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
CA2704473C (en) 2007-11-06 2016-10-04 Edison Pharmaceuticals, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
LT3827815T (lt) 2008-09-10 2023-10-10 Ptc Therapeutics, Inc. Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais
US10039722B2 (en) 2008-10-14 2018-08-07 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
EP2379710A1 (en) * 2008-12-19 2011-10-26 Schering Corporation Feed supplement for mammalian cell culture and methods of use
JP2012525399A (ja) 2009-04-28 2012-10-22 エジソン ファーマシューティカルズ， インコーポレイテッド トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療
CN103037839A (zh) * 2010-06-04 2013-04-10 全球药物科技有限公司 含有矫味剂的口服美其敏水性制剂
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
DE102014107132A1 (de) 2014-05-20 2015-11-26 Corden Pharma International Gmbh Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind
WO2016062269A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 阿那格雷在用于制备治疗癌症的医药组合物中的用途
HUE058877T2 (hu) 2014-12-16 2022-09-28 Ptc Therapeutics Inc (R)-2-hidroxi-2-metil-4-(2,4,5-trimetil-3,6-dioxociklohexa-1,4-dienil)butánamid polimorf és amorf alakjai
CA3008849A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337432C (en) * 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
PT801564E (pt) * 1994-12-28 2002-09-30 Janssen Pharmaceutica Nv Utilizacao de nebivolol como agente anti-aterogernico

Also Published As

Publication number Publication date
DE69526120D1 (de) 2002-05-02
JPH10511655A (ja) 1998-11-10
CZ287513B6 (en) 2000-12-13
MX9704669A (es) 1997-09-30
NO315687B1 (no) 2003-10-13
ATE214924T1 (de) 2002-04-15
NO972980D0 (no) 1997-06-26
SK282144B6 (sk) 2001-11-06
AU4347796A (en) 1996-07-19
CA2207333C (en) 2006-10-17
FI972793A (fi) 1997-06-27
HUT77927A (hu) 1998-11-30
KR100264348B1 (ko) 2000-08-16
CZ191997A3 (cs) 1999-01-13
DE69526120T2 (de) 2002-11-28
CN1167418C (zh) 2004-09-22
FI118884B (fi) 2008-04-30
EP0801564A1 (en) 1997-10-22
CN1171739A (zh) 1998-01-28
DK0801564T3 (da) 2002-07-15
PT801564E (pt) 2002-09-30
CA2207333A1 (en) 1996-07-04
FI972793A0 (fi) 1997-06-27
HU226208B1 (en) 2008-06-30
SK85697A3 (en) 2000-04-10
US5874461A (en) 1999-02-23
SI0801564T1 (en) 2002-08-31
US6075046A (en) 2000-06-13
NO972980L (no) 1997-06-26
WO1996019987A1 (en) 1996-07-04
EP0801564B1 (en) 2002-03-27
AU700364B2 (en) 1999-01-07
NZ298074A (en) 2001-01-26

Similar Documents

Publication Publication Date Title
ES2176354T3 (es) Uso de nebivolol como agente anti-aterogenico.
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
ES2157601T3 (es) Uso de agentes anti-microtubulos para tratar o prevenir la esclerosis multiple.
ES2163090T3 (es) Uso de toxina botulinica para tratar la cefalea tensional.
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ES2179351T3 (es) Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores.
ES2192839T3 (es) Timosina beta 4 oxidada.
MX9401807A (es) Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas.
BG101284A (en) Compounds and methods for cancer treatment
ES2078277T3 (es) Una nueva arginina desiminasa, su metodo de fabricacion y un agente anti-cancer que contiene esta enzima como un ingrediente eficaz.
ES2170798T3 (es) Benzopiranos y su uso como agentes terapeuticos.
BR0010515A (pt) Sistema terapêutico de ministração transdérmica, processo para mascarar um odor desagrádavel e uso de um óleo essencial em um sistema terapéutico de ministração transdérmica
ES2177849T3 (es) Preparado farmaceutico, que contiene 2-fenil-1,2-benzoisoselenazol-3(2h)-ona, para el tratamiento de la enfermedad de alzheimer.
ATE246929T1 (de) Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen
ATE528279T1 (de) 3-butenyl-1-aminederivate und ihre verwendung als ih modulatoren von therapie für psychiatrische erkrankungen
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
PT1133296E (pt) Nova aplicacao terapeutica da nicergolina
BR0009194A (pt) Composição do resorcinol
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2196171T3 (es) Agentes antitumorales de tioxantenona liofilizada.
SV2002000355A (es) Aril- y heteroarilsulfonatos ref. lea 34321-sv
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
ES2086526T3 (es) Aplicacion medicinal de m-csf.
IL143279A0 (en) Novel therapeutic application of low molecular weight heparin